SIGA Technologies CEO to Speak at NCT Europe on June 27, 2019
Dr. Gomez will present on “Medical Preparedness for Chemical, Biological, Radiological and Nuclear Defense (CBRNe) Incidents” at
A copy of the presentation will be available on the Investor Relations section of the Company’s website, under Events & Presentations, following the conclusion of the conference.
ABOUT
About Smallpox1
Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA’s filings with the Securities and Exchange Commission, including SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the
Contacts:
Investors
212-867-1768
dcarey@lazarpartners.com
Media
206-713-0124
sseiler@lazarpartners.com
1http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
Source: SIGA Technologies Inc.